Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilisation, Management and Avoidance
China Health and Retirement Longitudinal Study
Cancer Health Assessments Reaching Many
Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity
Crohn’s trial of the fully Human antibody Adalimumab for Remission Maintenance
Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity-Added
Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity-Alternative
Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity-Overall
Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity-Preserved
CHARité Berlin Morbide Adipositas iNtegrative Therapie-Studie
Comparing Hypertension Remote Monitoring Evaluation Redesign
Cross-checking on Reducing Adverse Events in the Emergency Department
The CHronic care for Age-Related Macular degeneration study
CHARM Echocardiographic Substudy
An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
Continuous Hormones As Replacement Therapy
Continuous Hyperfractionated Accelerated RadioTherapy
Fidelity monitoring across the seven studies in the Consortium of Hospitals Advancing Research on Tobacco
Characterization of heart failure patients with mid-range left ventricular ejection fraction
Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer
CNS HIV Antiretroviral Therapy Effects Research
Continuous Hyperfractionated Accelerated RadioTherapy Week-End Less
Coronary Health Assessment Study
Cardiovascular Health and Text Messaging
Child Health with Azithromycin Treatment
Childhood Adenotonsillectomy Trial
Community Health with Azithromycin Trial
Cardiovascular Health and Text Messaging- Diabetes Mellitus
Copenhagen Hospital Biobank - Cardiovascular Disease Cohort
Cluster Headache Cortivazol Injection
Social Insurance Institution’s Coronary Heart Disease Study
Confirmation that HEparin is an Alternative to Promote Early Reperfusion in acute myocardial infarction
Community Hypertension Evaluation Clinic program
Cohort Hip and Cohort Knee
Cardiovascular Health Evaluation to improve Compliance and Knowledge among Uninformed Patients
CHest pain Evaluation by Creatine Kinase MB, Myoglobin, And Troponin I
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Nivolumab in patients with advanced hepatocellular carcinoma
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma
An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
Nivolumab in metastatic urothelial carcinoma after platinum therapy
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer
Nivolumab versus sorafenib in advanced hepatocellular carcinoma
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer